We serve Chemical Name:4-benzamido-5-hydroxynaphthalene-2,7-disulfonic acid CAS:117-46-4 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:4-benzamido-5-hydroxynaphthalene-2,7-disulfonic acid
CAS.NO:117-46-4
Synonyms:EINECS 204-192-9;8-benzoylamino-3,6-disulfo-1-naphthol;1-benzoylamino-8-naphthol-3,6-disulfonic acid;4-benzoylamino-5-hydroxy-naphthalene-2,7-disulfonic acid;1-hydroxy-8-benzoylamino-naphthalene-3,6-disulphonic acid;H Acid,N-benzoyl;N-Benzoyl H-acid;4-Benzoylamino-5-hydroxy-naphthalin-2,7-disulfonsaeure
Molecular Formula:C17H13NO8S2
Molecular Weight:423.41700
HS Code:2924299090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:1.718g/cm3
Index of Refraction:1.742
PSA:174.83000
Exact Mass:423.00800
LogP:4.52570
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like EINECS 204-192-9 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,4-Benzoylamino-5-hydroxy-naphthalin-2,7-disulfonsaeure physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,H Acid,N-benzoyl Use and application,1-benzoylamino-8-naphthol-3,6-disulfonic acid technical grade,usp/ep/jp grade.
Related News: This also includes experience for drug delivery systems, efficient teams, facilities, and production capabilities. 5-Oxazolidinone, 2-(diphenylmethyl)-3-(trifluoroacetyl)-, (2S)- manufacturers Professor Xiangdong Cheng, secretary of party committee of Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital) and Chief of Zhejiang Province Upper Gastrointestinal Tumor Diagnosis and Treatment Technology Research Center, stated: The progress of immunotherapy in certain types of colorectal cancer and gastric cancer has not been satisfactory compared with the progress of anti-PD-1 monoclonal antibodies in melanoma, lung cancer and esophageal cancer, and this needs further exploration.
TIGIT is highly expressed in gastric cancer. And pre-clinical experiments have proved that synergistically targeting PD-1 and TIGIT could significantly repress gastric tumor growth. We look forward to the clinical results of IBI321, particularly in GI tumors.
Dr. Hui Zhou, Senior Vice President of Clinical Development of Innovent, stated: “By specifically targeting both PD-1 and TIGIT, this type of bispecific antibody is designed to provide synergistic effects by blocking both the PD-1/PD-L1 and TIGIT/CD155 pathways – with the goal of improving the anti-cancer efficacy.
Currently, there is no bispecific antibody that has same target as IBI321 in clinical-stage development worldwide. Preclinical studies of IBI321 have demonstrated that the combination of these two monoclonal antibodies further enhanced the immune activation with improved convenience of administration.
Therefore, the development of an anti-PD-1/TIGIT bispecific antibody has the potential to provide patients with more effective and convenient treatment. We look forward to hope that IBI321 will benefit more patients. nonaoxidane suppliers Systemic lupus erythematosus is an autoimmune disease in which the immune system attacks healthy tissue in the body. It is a chronic and complex disease with a variety of clinical manifestations that can impact many organs and can cause a range of symptoms including pain, rashes, fatigue, swelling in joints and fevers. 2-Pyrimidinamine, N-[[(4-chlorophenyl)thio]methyl]-4,6-dimethoxy- vendor & factory.
TIGIT is highly expressed in gastric cancer. And pre-clinical experiments have proved that synergistically targeting PD-1 and TIGIT could significantly repress gastric tumor growth. We look forward to the clinical results of IBI321, particularly in GI tumors.
Dr. Hui Zhou, Senior Vice President of Clinical Development of Innovent, stated: “By specifically targeting both PD-1 and TIGIT, this type of bispecific antibody is designed to provide synergistic effects by blocking both the PD-1/PD-L1 and TIGIT/CD155 pathways – with the goal of improving the anti-cancer efficacy.
Currently, there is no bispecific antibody that has same target as IBI321 in clinical-stage development worldwide. Preclinical studies of IBI321 have demonstrated that the combination of these two monoclonal antibodies further enhanced the immune activation with improved convenience of administration.
Therefore, the development of an anti-PD-1/TIGIT bispecific antibody has the potential to provide patients with more effective and convenient treatment. We look forward to hope that IBI321 will benefit more patients. nonaoxidane suppliers Systemic lupus erythematosus is an autoimmune disease in which the immune system attacks healthy tissue in the body. It is a chronic and complex disease with a variety of clinical manifestations that can impact many organs and can cause a range of symptoms including pain, rashes, fatigue, swelling in joints and fevers. 2-Pyrimidinamine, N-[[(4-chlorophenyl)thio]methyl]-4,6-dimethoxy- vendor & factory.
